The company has generated zero revenue over the last ten quarters while sustaining quarterly operating losses that reached $8.4 million in 2026Q1.
| Sales/Revenue | 0 | 0 | 0 | 675K | 951K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | -100% | -29.02% | - | - | - | - | - |
| Cost of Goods Sold | 211K | 572K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -211K | -572K | 0 | 675K | 951K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | 100% | 100% | - | - | - | - |
| Gross Profit Growth % | - | - | -100% | -29.02% | - | - | - | - | - |
| Operating Expenses | 29.75M | 28.95M | 32.12M | 21.45M | 19M | 8.98M | 2.02M | 1.96M | 952K |
| OpEx % of Revenue | - | - | - | 3177.63% | 1998.21% | - | - | - | - |
| Selling, General & Admin | 21.39M | 20.4M | 12.1M | 8.55M | 6.57M | 2.9M | 1M | 1.17M | 608K |
| SG&A % of Revenue | - | - | - | 1266.22% | 690.54% | - | - | - | - |
| Research & Development | 8.57M | 9.12M | 20.01M | 12.9M | 12.44M | 6.08M | 1.01M | 795K | 344K |
| R&D % of Revenue | - | - | - | 1911.41% | 1307.68% | - | - | - | - |
| Other Operating Expenses | -211K | -572K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -29.97M | -29.52M | -32.12M | -20.77M | -18.05M | -8.98M | -2.02M | -1.96M | -952K |
| Operating Margin % | - | - | - | -3077.63% | -1898.21% | - | - | - | - |
| Operating Income Growth % | - | 8.1% | -54.6% | -15.08% | -101.09% | -344.41% | -2.9% | -106.2% | - |
| EBITDA | -29.32M | -28.95M | -31.69M | -20.49M | -17.89M | -8.96M | 0 | 0 | 0 |
| EBITDA Margin % | - | - | - | -3035.56% | -1881.28% | - | - | - | - |
| EBITDA Growth % | 4.31% | 8.66% | -54.66% | -14.53% | -99.59% | - | - | - | - |
| D&A (Non-Cash Add-back) | 648K | 572K | 428K | 284K | 161K | 13K | 2.02M | 1.96M | 952K |
| EBIT | -35.51M | -26.48M | -36.66M | -30.46M | -18.05M | -9.39M | -2.02M | -2.03M | -952K |
| Net Interest Income | 1.12M | 941K | 1.19M | 533K | -6K | -628K | 0 | 0 | 0 |
| Interest Income | 1.18M | 1.01M | 1.26M | 615K | 0 | 0 | 244K | 139K | 168K |
| Interest Expense | 55K | 71K | 71K | 82K | 6K | 628K | 244K | 139K | 0 |
| Other Income/Expense | -9.98M | 2.96M | -4.61M | -9.77M | -6K | -1.04M | -244K | -202K | -168K |
| Pretax Income | -39.95M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M | -2.26M | -2.17M | -1.12M |
| Pretax Margin % | - | - | - | -4525.04% | -1898.84% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -39.95M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M | -2.51M | -2.3M | -1.12M |
| Net Margin % | - | - | - | -4525.04% | -1898.84% | - | - | - | - |
| Net Income Growth % | -162.89% | 27.7% | -20.25% | -69.14% | -80.27% | -299.4% | -8.85% | -105.71% | - |
| Net Income (Continuing) | -39.95M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M | -2.26M | -2.17M | -1.12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17 | -1.67 | -5.60 | -1.28 | -1.20 | -8.60 | -0.16 | -0.27 | -0.14 |
| EPS Growth % | 45.05% | 70.18% | -337.5% | -6.67% | 86.05% | -5275% | 40.74% | -92.86% | - |
| EPS (Basic) | - | -1.67 | -5.60 | -1.28 | -1.20 | -8.60 | -0.16 | -0.27 | -0.14 |
| Diluted Shares Outstanding | 239.08M | 158.87M | 6.7M | 2.45M | 1.51M | 1.17M | 1.52M | 847.15K | 794.32K |
| Basic Shares Outstanding | 239.08M | 158.87M | 6.7M | 2.45M | 1.51M | 1.17M | 1.52M | 842.5K | 794.32K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Binary Regulatory Funding Risk
According to the company's recent financial disclosures, Unicycive continues to sustain significant operating losses, with quarterly SG&A expenses reaching $6.8 million in 2026Q1, reflecting a shift toward commercial readiness that places substantial pressure on the firm's limited cash reserves of approximately $29.2 million.
The cost structure is currently dominated by rising administrative overhead, which appears to be scaling faster than the R&D intensity required for clinical development. This trend suggests that the company is front-loading commercialization costs before securing a definitive regulatory approval or a strategic partnership, which may exacerbate the risk of further shareholder dilution.
As reported in historical income statements, Unicycive's net income figures exhibit extreme volatility, including a $9.9 million gain in 2024Q2, which appears to be driven by non-operating items rather than core operational performance, complicating the assessment of the company's true underlying burn rate.
Investors should monitor these non-recurring items closely, as they mask the persistent cash-burning nature of the business model. The reliance on stock-based compensation, which remains a consistent feature of the expense profile, further suggests that the reported net losses may understate the true economic cost of operations.
Based on the provided financial data, Unicycive lacks any meaningful operating leverage, as the company has generated zero revenue over the last ten quarters while maintaining an average quarterly operating loss of approximately $7.5 million, highlighting the speculative nature of its current clinical-stage business model.
The absence of revenue generation means that every dollar of SG&A and R&D spending directly impacts the bottom line without any offsetting margin contribution. This lack of scale suggests that the company remains entirely dependent on external capital markets to fund its ongoing regulatory and administrative requirements.
While the 505(b)(2) regulatory pathway offers a potential shortcut to market, the company's lack of commercial infrastructure, as evidenced by the absence of revenue, suggests that Unicycive may struggle to gain formulary access against established incumbents with significantly larger sales forces and deeper market penetration.
The market may be underestimating the difficulty of displacing entrenched competitors in the hyperphosphatemia space, even with a superior pill-burden profile. Without a strategic partner to handle distribution and payer negotiations, the company's path to profitability appears highly uncertain and potentially capital-intensive.
Quick answers to the most common questions about buying UNCY stock.
For fiscal year 2025, Unicycive Therapeutics, Inc. (UNCY) reported total revenue of $0.0M.
Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $26.6M for the fiscal year ending 2025.